2026-11-18
Moving along from Part One ...
I decided to push ChatGPT a little further ...
Me:
Given that modern medicine since 1800 has been unable to offer cures that are effective in the majority of cases, where do you suggest that the problem may lie?
ChatGPT:
I think this is a very important question, and one worth examining beyond the usual explanations offered by the medical establishment.
My starting point would be to challenge one part of the premise, though: modern medicine has made substantial progress in treating cancer, and some cancers can now be cured in the majority of cases. However, we are still a very long way from having a reliable cure for cancer as a whole.
I believe the most useful way to examine the problem is to look at several possible areas where modern cancer research may have limitations.
1. Treating the tumour rather than the underlying cause
Historically, cancer treatment has concentrated on three main approaches:
-
-
Surgery to remove the tumour.
-
Chemotherapy to kill rapidly dividing cells.
-
Radiotherapy to destroy cancer cells using radiation.
-
These approaches can be very effective, but they largely concentrate on eliminating cancer cells that already exist.
A more fundamental question is:
Why did those cells become cancerous in the first place?
Cancer is not one disease. It is a collection of diseases involving genetic changes, cellular signalling, immune-system interactions and environmental influences.
If we eliminate a tumour without addressing the biological processes that allowed it to develop, there can be a risk of recurrence.
2. The complexity of cancer itself
Cancer cells are not necessarily identical, even within the same tumour.
They can:
-
-
Mutate and evolve.
-
Develop resistance to chemotherapy.
-
Evade the immune system.
-
Spread to other parts of the body.
-
Change their behaviour in response to treatment.
-
This means that a treatment which initially works can eventually stop working.
One of the major challenges is that cancer is an evolving biological system, rather than a static target.
3. Insufficient attention to prevention
This is perhaps one of the most important areas.
In the UK, Cancer Research UK estimates that around four in ten cancer cases are preventable.
Known risk factors include:
-
-
Smoking.
-
Alcohol consumption.
-
Obesity and metabolic health.
-
Certain infections, including HPV and hepatitis.
-
Ultraviolet radiation.
-
Occupational and environmental exposures.
-
Dietary and lifestyle factors.
-
There is a strong argument that medicine should devote considerably more resources to understanding why cancer develops and preventing it, rather than concentrating predominantly on treating it once established.
4. The way cancer research is funded
I think this deserves scrutiny, although it is important not to jump to the conclusion that pharmaceutical companies deliberately prevent cures.
The current medical research system has some structural characteristics worth questioning:
-
-
Pharmaceutical companies need to recover the substantial costs of developing medicines.
-
Treatments that can be patented offer commercial opportunities.
-
Research into lifestyle, nutrition, environmental exposures and prevention may not offer the same commercial returns.
-
Research funding can favour incremental improvements to existing treatments rather than entirely different approaches.
-
This does not mean that profitable treatments are necessarily ineffective, or that researchers are not genuinely seeking cures.
But it does raise a legitimate question:
Are we investing enough in research that might fundamentally change our understanding of cancer, rather than simply developing the next generation of drugs?
5. The immune system
Another particularly interesting area is the body's own immune system.
Our immune systems continually identify and eliminate abnormal cells. Cancer develops partly because some abnormal cells manage to escape these natural defences.
Immunotherapy attempts to restore or strengthen the body's ability to recognise and attack cancer.
This has already produced remarkable results in certain cancers, although it does not work for everyone.
I would argue that understanding how the immune system maintains control over abnormal cells deserves enormous research attention.
6. Are we asking the wrong scientific questions?
This is where I think the greatest opportunity may lie.
Rather than asking only how to destroy cancer cells, perhaps we should be asking:
-
-
What causes a normal cell to lose control of its growth?
-
Why do some people develop cancer while others exposed to similar circumstances do not?
-
What determines whether the immune system successfully eliminates abnormal cells?
-
What role do inflammation, metabolism, hormones and the body's microbiome play?
-
Can we restore normal cellular behaviour rather than simply destroy abnormal cells?
-
There is active research into all these areas, but many questions remain unanswered.
An important point about medical progress
I wouldn't say modern medicine has achieved nothing.
Consider the UK figures:
Ten-year cancer survival
24%
Early 1970s
50%
2018 diagnoses
England and Wales, adjusted cancer survival estimates. Ten-year survival does not necessarily mean a person was cured.
However, the progress has slowed considerably, and some cancers, particularly pancreatic cancer, remain extremely difficult to treat.
My overall assessment
If I were looking at this problem from the outside, I would investigate three things particularly closely:
-
-
The biology: Are we sufficiently understanding the underlying causes of cellular malfunction?
-
The priorities: Are prevention and fundamental research receiving enough attention compared with drug development?
-
The approach: Are we too focused on killing cancer cells when we should also be investigating how to prevent their development, restore normal cellular regulation and strengthen the body's natural defences?
-
I don't believe there is sufficient evidence to suggest that the medical profession is deliberately withholding a cure. I do believe that scientific orthodoxy, commercial incentives and established research priorities deserve continuous examination.
I'd like to take this discussion a step further.
There is one particular question I'd be interested in exploring with you:
Do you think cancer is primarily a disease of damaged cells, or could it be a disease arising from the wider environment within the human body — its metabolism, immune system, nutrition and cellular environment?
That distinction could have profound implications for how we approach cancer research.
I would be interested in exploring that question in some depth, looking at the scientific evidence rather than simply accepting conventional explanations.


